COMP <GO>
MEDP vs ABBV // PIOTROSKI F-SCORE QUALITY
Medpace Holdings Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: MEDP 6
— ABBV 8
■ METRIC PARITY
LAST: $652.01 (-3.77%) • MKT CAP: $18.95B
piotroski-score
7/9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDP VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDP | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.90% | 29.00% | -1.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.0x | 33.3x | +0.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 3.60% | 3.47% | +0.13 | MEDP | /fcf-yield <GO> |
| Operating Margin | 21.10% | 24.60% | -3.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 17.80% | 6.90% | +10.90 | MEDP | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 8.60% | +11.40 | MEDP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.13 | 5.33 | +3.80 | MEDP | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | MEDP | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.6 | 72.8 | -18.16 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.3x | 113.1x | -77.80 | MEDP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.95B | $513.86B | -$494.91B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDP REV | ABBV REV | MEDP GROSS % | ABBV GROSS % | MEDP FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $61.16B | 44.0% | 70.2% | $681.9M | $17.82B |
| FY 2024 | $2.11B | $56.33B | 44.0% | 70.0% | $572.3M | $17.83B |
| FY 2023 | $1.89B | $54.32B | 44.0% | 44.0% | $348.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDP // BETA 1.00
ABBV // BETA 1.15